Holen Sie sich die Stockscreener-App
88.37
8.91%
-8.64
Handel nachbörslich:
88.37
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx Biosciences (NASDAQ:INBX) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors? - simplywall.st
Trading the Move, Not the Narrative: (INBX) Edition - Stock Traders Daily
Inhibrx Biosciences expands clinical evaluation of Ozekibart in new cancer study cohorts - Traders Union
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position - Stock Titan
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing - Stock Titan
Inhibrx (INBX): Viking Global group discloses 9.3% beneficial ownership stake - Stock Titan
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained - TipRanks
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss - MarketBeat
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Inhibrx Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data - Stock Titan
FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart - Stock Titan
Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold" - MarketBeat
Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday - MarketBeat
(INBX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America - Stock Titan
Swiss National Bank Invests $968,000 in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Ongoing studies in rare cancer gain traction for Inhibrx Biosciences amid urgent patient needs - Traders Union
INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800 - TradingKey
Inhibrx Biosciences urges expanded research to address unmet needs in head and neck cancer - Traders Union
Inhibrx Biosciences, Inc. $INBX Shares Bought by SummitTX Capital L.P. - MarketBeat
TradingKey - TradingKey
Inhibrx Biosciences Inc (INBX) Balance Sheet - TradingKey
Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX - TradingView
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences: The Whole Story Rides On INBRX-106 (NASDAQ:INBX) - Seeking Alpha
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450 - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (INBX) for Rule-Based Strategy - Stock Traders Daily
Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile? - Sahm
Inhibrx Biosciences (INBX) Faces Headwinds as Stock Dips 1.89% – Support Test AheadChandelier Stop - dars.gov.et
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX) - Seeking Alpha
Inhibrx Biosciences Expands Credit Facility to $500 Million - TipRanks
Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million - Bitget
Inhibrx Biosciences Secures $500 Million Credit Facility with Oxford Finance to Accelerate Clinical Pipeline Expansion - Minichart
Inhibrx expands credit facility to $500 million with Oxford By Investing.com - Investing.com South Africa
Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants - TradingView
Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit - Stock Titan
Inhibrx Shares Fall After Expanding Loan Agreement to $500M - Moomoo
Inhibrx expands credit facility to $500 million with Oxford - Investing.com
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - PR Newswire
Inhibrx Gets $100 Million Now; Lenders May Fund $225 Million More - Stock Titan
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
Are you looking for a top momentum pick? Why Inhibrx Biosciences, Inc. (INBX) is a great choice - MSN
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice - Yahoo Finance
Top Cybin (HELP) Competitors 2026 - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Despite Modest Stock GainEarnings Growth Analysis - dars.gov.et
Inhibrx Biosciences (INBX) Stock Analysis Report | Financials & Insights - Benzinga España
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors - simplywall.st
(INBX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2500 Growth Benchmark - marketscreener.com
INBX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Company Reports No Revenue - dars.gov.et
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):